Lord's Mark Industries Limited has witnessed significant investor participation following a series of open-market transactions involving its promoter and marquee investors. According to reports from Business Standard, the transactions saw participation from Goldman Sachs Investments Mauritius I and AT Trade Overseas, owned by Hisaria Group, reflecting interest from established investment and business groups in the company. As reported by The Economic Times, the participation of marquee investors such as Goldman Sachs and the Hisaria Group adds further visibility to the company's evolving shareholder base and its presence in the public markets.
Goldman Sachs Investments Mauritius I Limited acquired 51 lakh shares of Lord's Mark Industries for ₹42.84 crore through a bulk deal on September 18, purchasing the equity shares at ₹84 per share. According to latest reports from LiveMint, this strategic investment by the global investment bank demonstrates confidence in the company's diversified business model and growth prospects across healthcare, diagnostics, renewable energy, and LED solutions. The transaction represents a significant vote of confidence from one of the world's most respected financial institutions in the small-cap stock.
Separately, the company's promoters sold 1.03 crore shares through a block deal/open-market transaction on BSE on September 18, generating ₹87.39 crore in proceeds. As reported by LiveMint, promoter Sachidanand H Upadhyay has confirmed the intention to reinvest the majority of the funds raised through the share sale. The proceeds are proposed to be deployed towards the expansion of the company's medical device unit through viable and acceptable means, with the company confirming that the proposed reinvestment will support its medical device expansion plans. This strategic move aligns with the company's focus on strengthening its healthcare and MedTech capabilities.
Lord's Mark Industries operates as a diversified BSE-listed company with operations spanning healthcare and MedTech, renewable energy and LED lighting, and specialised paper products. According to LiveMint, the company's healthcare and MedTech business manufactures diagnostic kits, biochemistry reagents and medical devices, while its renewable-energy division provides solar and smart-lighting solutions. For FY26, the company reported consolidated revenue of around ₹684.75 crore and net profit of ₹48.59 crore. In the June 2026 quarter, Lord's Mark Industries posted consolidated revenue of ₹307.68 crore and net profit of ₹33.18 crore, remaining profitable despite lower quarterly revenue compared to the preceding March quarter.
Lord's Mark Industries share price has delivered strong gains of 50% in less than two months, with the stock rising 8.87% over the past week, 12.10% over two weeks, and 11.66% over the past month. As reported by LiveMint, this robust performance reflects growing investor confidence in the company's diversified business model and execution capabilities across its healthcare, diagnostics, renewable energy, and LED solutions segments. The company's growing investor interest comes as it continues to strengthen its businesses, with focus on innovation, expansion and creating long-term value for stakeholders while executing its growth strategy across its diversified business verticals.
